| Literature DB >> 32668707 |
Fadillah Putri Patria1, Heidi Pekar1, Aida Zuberovic-Muratovic1.
Abstract
Ultra-performance hydrophilic interaction liquid chromatography tandem mass spectrometry system (UP-HILIC-MS/MS) was used in multi-toxin analysis of paralytic shellfish toxins (PSTs) and tetrodotoxins (TTXs) in sample matrices from bivalve molluscan species commercially produced for human consumption in Sweden. The method validation includes 17 toxins of which GTX6 and two TTX analogues, TTX and 4,9-anhydroTTX, were previously not analyzed together with hydrophilic PSTs. 11-deoxyTTX was monitored qualitatively with a non-certified reference standard. The performance of the method was evaluated for selectivity, repeatability, and linearity by analyzing spiked samples which generated linear calibration curves across the concentration ranges used (R2 > 0.99). The in-house reproducibility (RSD) was satisfactory including the LOD and LOQ for both PSP and TTX toxins being far below their regulatory action limits. The major advantage of the method is that it allows direct confirmation of the toxin identity and specific toxin quantification using a derivatization-free approach. Unlike the PST-chemical methods used in routine regulatory monitoring until now for food control, the UP-HILIC-MS/MS approach enables the calibration set-up for each of the toxin analogs separately, thereby providing the essential flexibility and specificity in analysis of this challenging group of toxins. The method is suitable to implement in food monitoring for PSTs and TTXs in bivalves, and can serve as a fast and cost-efficient screening method. However, positive samples would, for regulatory reasons still need to be confirmed using the AOAC official method (2005.06).Entities:
Keywords: UP-HILIC-MS/MS; bivalve mollusks; marine biotoxins; paralytic shellfish toxins; tetrodotoxin
Mesh:
Substances:
Year: 2020 PMID: 32668707 PMCID: PMC7404990 DOI: 10.3390/toxins12070452
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Illustration of the set-up of one single validation experiment. Three of such experiments were performed in a period of 2.5 months including 18 individual bivalve samples from three bivalve species (marked as a–f of total a-r included in the validation). S1–S6, for linearity, indicate calibration standards at six concentration levels covering slightly different concentration ranges for the different toxin analogues. Sum concentration of all PST analogues in S4 corresponds, approximately, to the regulatory limit level (RL) in monitoring of paralytic shellfish toxins (PSTs) in bivalves within the European Union (EU), 800 µg STXeq/kg. For TTX the RL recommended by EFSA, 44 µg TTX/kg, was used as reference, which approximately corresponds to TTX concentration in S5.
Figure 2MRM transitions of TTX analogues and some of the PST analogues critical in selectivity evaluation, spiked at mid-level concentrations (S4) in matrix extract from blue mussel. No difference in selectivity was observed between different species tested, blue mussel, oyster, and cockles. (MRM chromatograms of other toxins can be found in Supplementary Material Figure S2).
Linear regression parameters of solvent and matrix-matched calibration curves for seventeen toxin analogues. Matrix effect was evaluated as %ME calculated according to Equation (1) for each toxin: %ME = 100—no signal effect, %ME < 100—signal suppression, %ME > 100—signal enhancement. Italic values represent calibration range for TTX. Calibration curves of each toxin that visualize the signal suppression/enhancement can be found in Supplementary Material Figure S1.
| Table | Calibration Range | Correlation Coefficient ( | Matrix Effect (ME) | ||
|---|---|---|---|---|---|
| nmol/L | µg STX eq/kg | Solvent | Matrix-Match | %ME | |
| dcSTX | 4.1–130.0 | 21.0–671.5 | 0.995 | 0.998 | 59 |
| dcNEO | 1.9–60.8 | 5.25–167.9 | 0.991 | 0.995 | 69 |
| STX | 4.1–132.6 | 24.8–793.7 | 0,996 | 0.997 | 65 |
| NEO | 4.1–130.2 | 25.7–821.2 | 0.991 | 0.996 | 81 |
| TTX, 4-epiTTX | 4.9–157.2 |
|
|
| |
| 11-deoxyTTX | 0.2–5.0 |
|
|
| |
| 4,9-anhydroTTX | 0.6–19.8 |
|
|
| |
| dcGTX3 | 0.7–21.6 | 3.8–120.1 | 0.998 | 0.999 | 75 |
| GTX6 | 2.0–64.5 | 0.6–19.8 | 0.996 | 0.997 | 76 |
| GTX5 | 6.2–200.2 | 2.8–88.8 | 0.998 | 0.999 | 86 |
| C2 | 1.8–58.8 | 2.0–64.5 | 0.997 | 0.999 | 59 |
| GTX2 | 3.6–114.4 | 20.2–649.0 | 0.998 | 1.000 | 98 |
| GTX3 | 1.1–36.0 | 12.9–412.7 | 0.998 | 0.999 | 81 |
| GTX1 | 6.4–205.2 | 29.4–942.2 | 0.997 | 0.999 | 102 |
| GTX4 | 2.7–87.0 | 6.5–207.3 | 0.990 | 0.998 | 93 |
| dcGTX2 | 3.7–117.0 | 20.3–649.0 | 0.996 | 0.999 | 73 |
| C1 | 0.8–25.0 | 0.67–21.6 | 0.999 | 0.999 | 51 |
Recovery values in sample preparation for spiked crude extracts of individual blue mussel samples, calculated from peak areas. Spiked concentrations in nmol/L and corresponding in µg STXeq/kg of each toxin and the recovery percentages for within- and between-batch repeatabilities. RSDr: within-batch repeatability. RSDR: between-batch repeatability. All values are based on three repetitions and nine injections. Italic values represent TTX.
| Toxins | Conc. in Spiked Sample | Mean Recovery ( | RSDr (%) | RSDR (%) | |
|---|---|---|---|---|---|
| nmol/L | µg STX eq/kg | ||||
| dcSTX | 16.25 | 83.94 | 66 | 7 | 18 |
| dcNEO | 7.60 | 20.99 | 62 | 10 | 22 |
| STX | 16.58 | 99.21 | 65 | 5 | 15 |
| NEO | 16.28 | 102.63 | 65 | 8 | 19 |
| TTX, 4-epiTTX | 19.65 |
|
|
|
|
| 11-deoxyTTX | 0.63 |
|
|
|
|
| 4,9-anhydroTTX | 2.48 |
|
|
|
|
| dcGTX3 | 7.35 | 15.01 | 68 | 6 | 14 |
| GTX6 | 14.62 | 2.47 | 34 | 24 | 52 |
| GTX5 | 3.13 | 11.09 | 61 | 7 | 18 |
| C2 | 8.48 | 8.06 | 54 | 20 | 23 |
| GTX2 | 25.65 | 81.13 | 62 | 19 | 24 |
| GTX3 | 10.88 | 51.59 | 66 | 11 | 16 |
| GTX1 | 14.30 | 117.64 | 64 | 18 | 25 |
| GTX4 | 4.50 | 25.91 | 74 | 12 | 30 |
| dcGTX2 | 25.03 | 34.07 | 70 | 10 | 16 |
| C1 | 28.35 | 2.70 | 49 | 30 | 31 |
Summary of the repeatability evaluation. Table shows values for within-batch repeatability (RSDr) and between-batch repeatability (RSDR) for each PST and TTX analogue at high, mid and low concentration in pool extracts of blue mussels. * Concentrations for TTXs are expressed in µg TTX/kg.
| Toxins | High-Level | Mid-Level | Low-Level | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Conc (µg STX eq/kg) * | %RSDr ( | %RSDR ( | Conc (µg STX eq/kg) * | %RSDr ( | %RSDR ( | Conc (µg STX eq/kg) * | %RSDr ( | %RSDR ( | ||
|
| 335.66 | 2 | 9 | 86.06 | 3 | 5 | 43.44 | 4 | 11 | |
|
| 84.31 | 3 | 8 | 21.98 | 6 | 7 | 11.93 | 6 | 10 | |
|
| 395.35 | 4 | 7 | 102.47 | 2 | 4 | 53.87 | 2 | 10 | |
|
| 411.77 | 3 | 10 | 105.75 | 4 | 6 | 54.29 | 4 | 9 | |
|
| 501.89 | 2 | 7 | 124.71 | 3 | 6 | 64.94 | 4 | 5 | |
|
| 14.56 | 4 | 9 | 3.82 | 8 | 14 | 2.00 | 9 | 12 | |
|
| 55.01 | 3 | 12 | 14.22 | 12 | 13 | 7.41 | 10 | 16 | |
|
| 74.82 | 2 | 3 | 19.52 | 3 | 3 | 10.65 | 3 | 3 | |
|
| 9.91 | 3 | 10 | 2.53 | 5 | 12 | 1.25 | 10 | 15 | |
|
| 43.70 | 1 | 6 | 11.15 | 2 | 7 | 5.88 | 3 | 9 | |
|
| 29.85 | 3 | 15 | 7.86 | 5 | 13 | 4.26 | 8 | 9 | |
|
| 313.05 | 5 | 8 | 81.00 | 4 | 7 | 40.55 | 5 | 7 | |
|
| 198.16 | 6 | 8 | 52.38 | 6 | 6 | 27.90 | 7 | 9 | |
|
| 470.33 | 5 | 6 | 117.73 | 5 | 4 | 58.58 | 6 | 8 | |
|
| 105.04 | 8 | 11 | 27.93 | 9 | 10 | 14.22 | 15 | 18 | |
|
| 133.61 | 3 | 5 | 34.21 | 5 | 6 | 17.28 | 6 | 6 | |
|
| 9.99 | 3 | 5 | 2.67 | 5 | 10 | 1.57 | 6 | 18 | |
LOQ and LOD level for each PST and TTX. * These values correspond to a higher LOQ, which is calibration solution S5.
| Toxins | LOQ Conc | LOD Conc |
|---|---|---|
| (µg STX eq/kg or µg TTX/kg) | ||
| dcSTX | 20.99 | 2.62 |
| dcNEO | 5.25 | 2.62 |
| STX | 24.80 | 3.10 |
| NEO | 25.66 | 6.41 |
| TTX, 4-epiTTX | 15.68 | 7.84 |
| 11-deoxyTTX | 1.89 * | 0.95 |
| 4,9-anhydroTTX | 7.45 * | 3.73 |
| dcGTX3 | 3.75 | 0.94 |
| GTX6 | 0.62 | 0.31 |
| GTX5 | 2.77 | 0.35 |
| C2 | 2.01 | 0.50 |
| GTX2 | 20.28 | 2.54 |
| GTX3 | 12.90 | 6.45 |
| GTX1 | 29.41 | 14.71 |
| GTX4 | 12.96 * | 6.48 |
| dcGTX2 | 8.52 | 4.26 |
| C1 | 0.67 | 0.08 |
Information of the certified reference standard for each toxin and the concentrations. * non-certified reference value.
| Certified Reference Standard | Containing Toxins | Concentration (µmol/L) | Commercial Provider |
|---|---|---|---|
| CRM-dcGTX2&3-c | dcGTX2 | 100.1 | NRCC, NS, Canada |
| dcGTX3 | 29.4 | ||
| CRM-dcSTX-b | dcSTX | 65 | |
| CRM-GTX1&4-d | GTX1 | 57.2 | |
| GTX4 | 18 | ||
| CRM-GTX2&3-d | GTX2 | 102.6 | |
| GTX3 | 43.5 | ||
| CRM-NEO-d | NEO | 65.1 | |
| CRM-STX-f | STX | 66.3 | |
| CRM-C1&2-b | C1 | 113.4 | |
| C2 | 33.9 | ||
| CRM-dcNEO-d | dcNEO | 30.4 | |
| CRM-GTX5-c | GTX5 | 55.7 | |
| CRM-GTX6 | GTX6 | 12.5 | |
| GTX5 | 2.79 | ||
| CRM-03-TTXs | TTX | 78.6 | CIFGA; Lugo, Spain |
| 4,9-anhydro TTXs | 9.9 | ||
| 11-deoxyTTX * | 2.50 |
MRM transitions in positive ESI mode. The MRM method was built by grouping of toxins with similar retention times in chromatographic separation. Bold ions indicate primary MRM transition for quantification of corresponding analogues. * Toxins for which no primary certified reference standard was available on the market.
| Time Windows Group | Analytes | Precursor Ion, | Product Ion, | Cone, V | Dwell, ms | CE, eV |
|---|---|---|---|---|---|---|
| 1 | * dido-dcSTX |
| 10 | 40 | 15 | |
| 2 | STX |
| 10 | 40 | 24; 30 | |
| NEO |
| 298.1; 220.1; | 10 | 40 | 15; 24; 26 | |
| dcSTX |
| 222; | 10 | 40 | 22; 19 | |
| dcNEO |
| 225.1; | 10 | 40 | 18; 20 | |
| * doSTX |
| 206.1; | 10 | 40 | 22; 23 | |
| 3 | TTX, 4-epi TTX |
| 40 | 25 | 38; 25 | |
| 11-deoxy TTX |
| 176.1; 286.1 | 40 | 25 | 30 | |
| 4,9-Anhydro TTX |
| 162.1; 256.1 | 40 | 25 | 30 | |
| * 11-nor TTX-6-ol | 290.1 | 162.1; 272.1 | 40 | 25 | 30 | |
| * 5,6,11-Trideoxy TTX | 272.1 | 162.1; 254.1 | 40 | 25 | 30 | |
| 4 | GTX3 | 396.1 | 298.1 | 10 | 50 | 17 |
| GTX4 | 412.1 | 314.1 | 10 | 50 | 18 | |
| dcGTX3 |
|
| 10 | 50 | 18 | |
| * dcGTX4 |
|
| 10 | 50 | 18 | |
| 5 | GTX5 |
|
| 10 | 100 | 16 |
| GTX6 |
|
| 10 | 100 | 15 | |
| 6 | C1 | 396.1 | 298.1 | 18 | 40 | 20 |
| C2 |
|
| 18 | 40 | 20 | |
| * C3 | 412.1 | 332.1; 314.1 | 18 | 40 | 16; 20 | |
| * C4 |
| 332.1; | 18 | 40 | 16; 20 |
MRM transitions in negative ESI mode. The MRM method was built by grouping of toxins with similar retention times in chromatographic separation. Bold ions indicate primary MRM transition for quantification of corresponding analogues.
| Time Windows Group | Analytes | Precursor Ion, | Product Ion, | Cone, V | Dwell, ms | CE, eV |
|---|---|---|---|---|---|---|
| 1 | GTX2 |
| 10 | 60 | 16, 22 | |
| GTX3 |
| 351.1; | 10 | 60 | 16; 22 | |
| GTX1 |
| 10 | 60 | 15; 22 | ||
| GTX4 |
| 367.1; | 10 | 60 | 15; 22 | |
| dcGTX2 |
| 333.1; | 10 | 60 | 17; 30 | |
| dcGTX3 | 351.1 | 333.1; 164.0 | 10 | 60 | 17; 30 | |
| 2 | GTX5 | 378.1 | 122 | 10 | 100 | 25 |
| GTX6 | 394.1 | 122 | 10 | 100 | 25 | |
| 3 | C1 |
| 351.1; | 10 | 40 | 25; 30 |
| C2 | 474.1 | 351.1; 122.0 | 10 | 40 | 25; 30 |